Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | GCK | P35557 | 8/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635198 | 0.91 | KCNH2 (0.58) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4635185 | 0.85 | KCNH2 (0.66) | KCNH2CYP11B1CYP11B2PGR | |
| SCHEMBL4634238 | 0.84 | KCNH2 (0.62) | KCNH2CYP11B1CYP11B2PGR | |
| SCHEMBL509350 | 0.82 | KCNH2 (0.61) | KCNH2CYP11B1CYP11B2PGR | |
| SCHEMBL4635956 | 0.80 | KCNH2 (0.61) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4635181 | 0.79 | KCNH2 (0.58) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL2717764 | 0.78 | KCNH2 (1.00) | KCNH2CYP11B1CYP11B2PGR | |
| SCHEMBL509689 | 0.78 | KCNH2 (0.79) | KCNH2CYP11B1CYP11B2PGR | |
| SCHEMBL509289 | 0.76 | KCNH2 (0.65) | KCNH2CYP11B1CYP11B2PGR | |
| SCHEMBL5226016 | 0.75 | KCNH2 (0.54) | KCNH2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556359-B1 | PYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS FOR HIV MEDIATED DISEASES | PFIZER LTD (GB) | 2008-06-18 | — | — | EP | disclosed |
| US-7220772-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220772-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1556359-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS FOR HIV MEDIATED DISEASES | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050054707-A1 | Pyrazole derivatives | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2004031156-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS FOR HIV MEDIATED DISEASES | PFIZER LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054707-A1 | Pyrazole derivatives | RTF1, PDCD11, RRM2B | KCNH2 3264/4885CYP11B1 524/4885CYP11B2 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.